Autopsy report · NCT04685915

Copanlisib Plus Ibrutinib or Acalabrutinib in R/R CLL

“Bayer is no longer funding due to lack of accrual”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Phase

Phase 2

Sponsor

Inhye Ahn

Sponsor type

University, hospital or other

Conditions

Chronic Lymphocytic Leukemia (CLL)

Interventions

Ibrutinib; Copanlisib; Acalabrutinib

Participants

0

Trials that died the same way

• Stereotactic Radiation Therapy and Sorafenib in the Treatment of Hepatocellular Carcinoma
  “Sponsor(Bayer)did not wish to continue with study due to slow accrual. Therefore, there is insufficient data and will not be any study results/outcomes.” (74% match in meaning)
• Azacitidine and Lintuzumab in Treating Patients With Previously Untreated Myelodysplastic Syndromes
  “Drug no longer being supplied by sponsor” (62% match in meaning)
• Muscle, Essential Amino Acids, and eXercise in Heart Failure
  “There is no longer any funding to support the study” (59% match in meaning)
• Intravenous Ketamine Effects on Functional Neuroanatomy
  “Sponsor is no longer interested in funding the study” (58% match in meaning)
• Efficacy and Pharmacogenomics of Cladribine Based Salvage Chemotherapy in Patients With Relapse/Refractory and Secondary Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS)
  “No longer have funding support to complete the pharmacogenetics component.” (58% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.